Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.

Saved in:
Bibliographic Details
Title: Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Authors: Popescu B; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Jones MF; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Piao M; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Tran E; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Koh A; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Lomeli I; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Peretz CAC; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Murad N; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Abelson S; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Morales C; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Rivera JM; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Batingana AR; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., D'Souza J; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Pikman Y; Division of Hematology and Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, MA., Cheng ML; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Logan AC; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA., Huang BJ; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Stieglitz E; Division of Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA., Smith CC; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.
Source: Blood [Blood] 2026 Jan 15; Vol. 147 (3), pp. 276-289.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025030558